Sanofi enlists Emcure for cancer-drug marketing in India

Shailesh Ayyangar

Sanofi's ($SNY) known for its emerging-markets prowess, but we all need a little help sometimes. To aid it with marketing its oncology lineup in India, the French drugmaker has brought on local company Emcure Pharmaceuticals, PMLiVE reports. Emcure will be responsible for drugs Taxotere, Jevtana, Fludara and Fasturtec, and doctors and patients "will now have access--under one roof--to one of the most comprehensive and complementing oncology portfolios in India," Shailesh Ayyangar, head of Sanofi's Indian subsidiary, told the publication. Report | More

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.